Global Healthcare Licensing Database

As more and more progress in the life sciences sector occurs by a combination of different technologies, the growth of agreements implying activities of research and development, co-promoting and co-marketing has been strong. These licensing arrangements influence the healthcare markets and are therefore an important factor for consideration for companies for their healthcare investments.

HealthcareBizintelli compiles a database for all such licensing deals and negotiations that take place among global healthcare companies and provides 250, 500, 1000, 1500, 2000 or 2500 records as needed by the user. These records can be selected by the user for various sub-groups such as key regions, sub-industries, market capitalization groups, key countries, and major medical groups. Also the user can select combinations of these sub-groups.

Our global healthcare licensing database contains all the details of a healthcare licensing deal/transaction taken place between two companies/institutes. These two companies/institutes are marked with prefix A and prefix B in our database. Further, to simplify the compilation of the database we have bifurcated such licensing deals/transactions in three key clusters i.e. Japan-US, Japan-Europe, and US-Europe. And, the licensing deals/transactions related to countries/regions other than these are assigned other related clusters.

The detailed explanation of the data items included in the Global Licensing Database is provided here.

➢ Global healthcare companies to be updated with the different kinds of licensing options being pursued worldwide➢ Global healthcare companies planning to introduce products in other countries➢ Companies active in R&D and seeking new market base with a profitable licensing deal➢ Healthcare company executives negotiating licensing deals with various payment options➢ Investors analyzing varied kinds of transaction options available globally for licensing deals

Select Sub-Groups (Licensing deals totals from January 2018 to July 2019):